pc:ver0l

Verismo Therapeutics

A clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology to develop targeted cell therapies for cancer. Focused on advancing clinical-stage programs, including SynKIR™-110 for advanced solid tumors and SynKIR™-310 for B cell non-Hodgkin lymphoma.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―

Estimated Valuation―

Total Amount Raised$28M

Total Amount Raised$28M

Total Funding Rounds1

Total Funding Rounds1

Latest Funding Amount$28M

Latest Funding Amount$28M

Latest Funding RoundInvestment

Latest Funding RoundInvestment

Post-Money Valuation―

Post-Money Valuation―

Funding Round

Apr 15, 2026

Investment

$28.00M

―

Investors

Investment

Related News and Analysis

Verismo Therapeutics Posts Early Clinical Wins for KIR-CAR Pipeline in Blood and Solid Tumors

Verismo Therapeutics Posts Early Clinical Wins for KIR-CAR Pipeline in Blood and Solid Tumors

Verismo Therapeutics advanced its KIR-CAR cell therapy platform this week, releasing early but promising data for both hematologic...

5d ago

Verismo Showcases Early SynKIR-310 Data, Signals Potential Step-Change in CAR T for B-Cell Lymphomas

Verismo Showcases Early SynKIR-310 Data, Signals Potential Step-Change in CAR T for B-Cell Lymphomas

New updates have been reported about Verismo Therapeutics. Verismo Therapeutics has released new preclinical and early clinical data...

9d ago

Verismo Reports Encouraging First-in-Human Data for SynKIR-110 in Solid Tumors

Verismo Reports Encouraging First-in-Human Data for SynKIR-110 in Solid Tumors

New updates have been reported about Verismo Therapeutics. Verismo Therapeutics has reported its first human data for SynKIR-110,...

10d ago

Verismo to Unveil First-in-Human KIR-CAR Data for SynKIR-110 and SynKIR-310 at AACR 2026

Verismo to Unveil First-in-Human KIR-CAR Data for SynKIR-110 and SynKIR-310 at AACR 2026

New updates have been reported about Verismo Therapeutics. Verismo Therapeutics will showcase pivotal first-in-human and preclinical data for...

15d ago

Verismo Therapeutics Secures $28 Million to Advance KIR-CAR Trials Ahead of Key 2026 Data Readout

Verismo Therapeutics Secures $28 Million to Advance KIR-CAR Trials Ahead of Key 2026 Data Readout

New updates have been reported about Verismo Therapeutics. Verismo Therapeutics has obtained a $28 million capital infusion from...

15d ago

Manifest Hires AI Veteran as CPTO to Accelerate Vertical SaaS Push for Small Businesses

Manifest Hires AI Veteran as CPTO to Accelerate Vertical SaaS Push for Small Businesses

New updates have been reported about Manifest. Manifest has appointed AI-focused entrepreneur and inventor Zack Avshalomov as Chief...

3h ago

FloodMapp Showcases Flood-Impact Analytics for Texas Hill Country Event

FloodMapp Showcases Flood-Impact Analytics for Texas Hill Country Event

A LinkedIn post from FloodMapp describes how the company’s post-event flood intelligence was applied to the July 2025...

4h ago

Firmus Technologies Advances Billion-Dollar AI Infrastructure Build With NVIDIA GB300 Deployment

Firmus Technologies Advances Billion-Dollar AI Infrastructure Build With NVIDIA GB300 Deployment

According to a recent LinkedIn post from Firmus Technologies, the company’s board and executive leadership recently toured one...

4h ago

Vitalchat Targets Business Development Opportunities at Florida Healthcare Innovation Summit

Vitalchat Targets Business Development Opportunities at Florida Healthcare Innovation Summit

A LinkedIn post from Vitalchat highlights the company’s planned participation in the Florida Healthcare Innovation Summit organized by...

4h ago

FriendliAI Enhances AI Endpoint Performance With Host KV Cache Capability

FriendliAI Enhances AI Endpoint Performance With Host KV Cache Capability

According to a recent LinkedIn post from FriendliAI, the company is highlighting an infrastructure feature for its Friendli...

4h ago